MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    a-synuclein neurotoxicity and spreading using Lewy Body extracts from Parkinson Disease Brains: In vitro screening by cell-based assays

    E. Bezard, F. Cavaliere, L. Cerf, B. Dehay, P. Ramos-Gonzalez, F. De Giorgi, M. Bourdenx, A. Bessede, J. Obeso, F. Ichas, C. Matute (Bordeaux, France)

    Objective: To define the kinetics of neuronal and astrocytic abnormalities induced by human-derived α-syn aggregates for grounding the use of such system to identify and…
  • 2017 International Congress

    Detection of Early Changes in Microbiota Composition in Prodromal Parkinson’s Disease

    J. Boertien, T. Van Laar (Groningen, Netherlands)

    Objective: To identify predictive markers of Parkinson’s disease (PD) in the gut microbiota composition of subjects at risk for developing PD due to a positive…
  • 2017 International Congress

    Alpha-synuclein protein homeostasis and oligomerization in iron-overloaded cells expressing mutant HFE

    Y. Kim, J. Connor, M. Stahl (Hershey, PA, USA)

    Objective: Study the direct and indirect effects of iron overload on alpha synuclein homeostasis in a genetic model of hemochromatosis (HFE) Background: Parkinson’s disease (PD)…
  • 2017 International Congress

    FXTAS, PD, and ET subjects demonstrate distinct gait, balance and tremor deficits under normal, environmentally challenging, and dual-task conditions

    E. Robertson, D. Hall, A. McAsey, M. Swanson, A. Bery, C. Huml, E. Berry-Kravis, J. O'Keefe (Chicago, IL, USA)

    Objective: To compare FXTAS, PD, ET and controls using quantitative measures of gait, balance, and tremor. Background: Fragile X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative disease…
  • 2017 International Congress

    Familial idiopathic basal ganglia calcification with novel SLC20A2 gene variant

    B. Barton (Chicago, IL, USA)

    Objective: Describe a family with brain calcifications related to new pathogenic variant of SLC20A2 gene. Background: Three genes are associated with the rare occurrence of autosomal…
  • 2017 International Congress

    Assessing Parkinson’s disease motor symptoms using supervised learning algorithms

    P. Angeles, Y. Tai, N. Pavese, R. Vaidyanathan (London, United Kingdom)

    Objective: Implantable brain stimulators are now an established method of treating Parkinson’s Disease (PD). Determination of optimal neural stimulation parameters is complex and clinically demanding. The goal of…
  • 2017 International Congress

    Final validation of an electronic diary for motor fluctuations and dyskinesias evaluation in PD patients: Comparison with paperback diary.

    C. Terroba, A. Medina, F. Nanni, V. Bruno, D. Cerquetti, M. Rossi, M. Merello (Buenos Aires, Argentina)

    Objective: To determine the reliability and compliance to an electronic motor diary in PD patients.  Background: Despite paper diaries are widely used, adherence, duplication, fraudulent…
  • 2017 International Congress

    Direct dopaminergic responsiveness of activity performance

    P. Hagell, G.-M. Hariz, B. Sandlund (Kristianstad, Sweden)

    Objective: To assess the direct dopaminergic responsiveness of motor and process aspects of activity performance in people with parkinsonian disorders, and to compare this to…
  • 2017 International Congress

    Comparison of neurotoxic potency of a newly produced Botulinum Neurotoxin Type A with onabotulinumtoxinA, incobotulinumtoxinA and BotulinumtoxinA

    Y. Feng, W. Liu, L. Pan, Z. Nie (Shanghai, China)

    Objective: This study aims to compare the neurotoxic potency of four different kinds of toxins, accompanied with expression level changes of key factors after BoNT/A…
  • 2017 International Congress

    Inhaling xenon ameliorates L-DOPA-induced dyskinesia in Parkinson disease through normalizing maladaptive corticostriatal plasticity

    E. Bezard, J. Bauffreton, Q. Li, G. Porras, W.K. Ko, E. Pioli, M. Cazalon, S. Morin, G. Farjot, J. Pype, B. Bessiere (Bordeaux, France)

    Objective: To investigate the mechanism(s) of action of xenon inhalation for the treatment of L-DOPA-induced dyskinesia. Background: L-dopa-induced dyskinesia (LID) is one of the most…
  • « Previous Page
  • 1
  • …
  • 138
  • 139
  • 140
  • 141
  • 142
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley